Does Medicare cover GLP-1 for weight loss? - Reddit

Why does Medicare not cover GLP-1 drugs for weight loss?

Medicare Part D — the prescription drug benefit — has historically excluded drugs prescribed solely for weight loss or weight management. That exclusion is statutory: the Medicare Modernization Act of 2003 explicitly lists weight-loss drugs among the categories Part D plans are not required to cover.

This means that GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound), which received FDA approval for chronic weight management, are generally not covered under Medicare Part D when prescribed for that indication. The same molecules, marketed under different brand names for type 2 diabetes (Ozempic for semaglutide, Mounjaro for tirzepatide), can be covered under Part D — but only when prescribed for the diabetes indication, not off-label for weight management.

What is the diabetes exception?

If you have a Medicare Part D plan and a type 2 diabetes diagnosis, your plan may cover Ozempic (semaglutide) or Mounjaro (tirzepatide) as diabetes medications. Whether they are covered depends on your specific plan formulary, prior-authorization requirements, and tier placement.

The important distinction: coverage for the diabetes indication does not extend to using these drugs for weight management alone. If your physician prescribes semaglutide specifically for weight loss — not diabetes — Medicare Part D is generally not required to pay for it.

Medicare Advantage (Part C) plans are also bound by this statutory exclusion and generally follow the same rules, though plan designs vary. Always verify your specific plan’s formulary directly with your plan administrator.

What legislation could change GLP-1 coverage?

The Treat and Reduce Obesity Act has been introduced multiple times in Congress and would allow Medicare to cover FDA-approved weight-management medications, including GLP-1 drugs, for obesity treatment. As of the time of writing, this legislation has not been enacted into law.

The Biden administration in 2024 proposed a rule that would expand Medicare Part D coverage for anti-obesity medications, but the regulatory trajectory of that proposal has been uncertain. This is a fast-moving policy area — check CMS.gov for the most current guidance before making coverage assumptions.

What does Medicare Part B cover for obesity?

Medicare Part B does cover intensive behavioral therapy (IBT) for obesity — which includes individual counseling sessions with a primary care physician, focused on diet and exercise. This is limited in scope and does not include prescription drug coverage.

Some Medicare beneficiaries are also eligible for bariatric surgery coverage under Part A if they meet specific clinical criteria. This is unrelated to GLP-1 drug coverage but is part of the broader landscape of what Medicare does and does not pay for in weight management.

What are my options for GLP-1 access when Medicare does not cover it?

For Medicare beneficiaries or others without GLP-1 coverage, clinician-supervised telehealth programs have become a significant access pathway. These programs work differently from branded pharmacy channels:

• Clinician evaluation: A licensed clinician reviews your health history, goals, and eligibility before any prescription is written.
• Compounded formulations: Rather than brand-name Wegovy or Zepbound at retail prices, eligible patients can access compounded semaglutide or tirzepatide from licensed 503A pharmacies in the USA. Compounded versions contain the active ingredient but are not FDA-approved drugs in their own right.
• No hidden overseas supply chain: Reputable programs source exclusively from USA-based 503A compounding pharmacies — not overseas manufacturers or unregulated gray-market vendors.
• Out-of-pocket cost: Compounded programs are significantly less expensive than retail brand-name pricing, though they are still out-of-pocket. Consult fees, monthly supply costs, and check-in costs vary by program.

This pathway is not a Medicare workaround — it operates entirely outside Medicare as a private-pay arrangement. But for those who cannot access coverage, it represents a clinically supervised alternative to gray-market sourcing.

Why is compounded not the same as brand-name?

Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies using the active pharmaceutical ingredient. They are not FDA-approved in their compounded form — the FDA approval for semaglutide applies to the branded Ozempic and Wegovy formulations manufactured by Novo Nordisk, not to compounded versions.

This matters for informed consent. If a clinician prescribes a compounded GLP-1, you should understand that it has not undergone the same FDA drug approval process as the branded version. The active ingredient is the same, but the compounded product as dispensed has not been individually reviewed and approved by the FDA.

That said, compounding from a licensed 503A pharmacy in the USA under physician supervision is a legal and regulated activity — it is meaningfully different from ordering peptides or pharmaceuticals from overseas vendors operating outside U.S. regulatory oversight.

Frequently asked questions